Valuation: Denali Therapeutics Inc.

Market Cap 298.59Cr 266.08Cr 246.34Cr 222.93Cr 420.01Cr 28TCr 424.99Cr 2.95TCr 1.16TCr 15TCr 1.12TCr 1.1TCr 47TCr P/E 2026 *
-8.21x
P/E 2027 * -8.1x
Enterprise Value 227.75Cr 202.95Cr 187.9Cr 170.04Cr 320.37Cr 21TCr 324.16Cr 2.25TCr 883.98Cr 11TCr 854.37Cr 836.59Cr 36TCr EV / Sales 2026 *
45x
EV / Sales 2027 * 17.1x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.32%
1 week+4.53%
Current month-9.63%
1 month-8.74%
3 months-21.61%
6 months-7.20%
Current year+13.14%
1 week 17.33
Extreme 17.33
19.35
1 month 17.33
Extreme 17.33
21.51
Current year 15.34
Extreme 15.34
27.3
1 year 13.75
Extreme 13.75
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
56.08
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Chief Technology Officer

-1,654 0.0010%
02/09/26 Sell

Director

-11,439 0.0072%
01/09/26 Sell

Founder

-2,768 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.32%+4.53%+10.14%+1.97% 298.59Cr
-0.21%-4.43%+44.40%+74.13% 6.62TCr
-3.79%-0.13%+6.82%+68.02% 5.52TCr
+0.26%+3.35%+11.43%+90.48% 5.28TCr
+3.28%+5.58%+26.51%+50.05% 4.55TCr
+0.51%+9.95%+22.40%+133.92% 4.39TCr
-1.15%+0.39%+263.21%+594.60% 4.16TCr
+0.10%+9.90%+16.11%+59.33% 3.4TCr
-8.38%-6.95%+26.35%-1.93% 2.58TCr
-0.80%+2.85%+35.47%+25.47% 2.35TCr
Average -1.13%+4.12%+46.28%+109.60% 3.92TCr
Weighted average by Cap. -0.80%+3.73%+48.93%+124.94%

Financials

2026 *2027 *
Net sales 5.07Cr 4.51Cr 4.18Cr 3.78Cr 7.12Cr 477.98Cr 7.21Cr 50Cr 20Cr 251.24Cr 19Cr 19Cr 800.6Cr 13Cr 12Cr 11Cr 9.75Cr 18Cr 1.23TCr 19Cr 129.22Cr 51Cr 648Cr 49Cr 48Cr 2.06TCr
Net income -44Cr -40Cr -37Cr -33Cr -63Cr -4.2TCr -63Cr -439.99Cr -172.65Cr -2.21TCr -166.86Cr -163.39Cr -7.03TCr -45Cr -40Cr -37Cr -34Cr -63Cr -4.25TCr -64Cr -445.91Cr -174.96Cr -2.24TCr -169.1Cr -165.58Cr -7.13TCr
Net Debt -71Cr -63Cr -58Cr -53Cr -100Cr -6.69TCr -100.83Cr -700.74Cr -274.96Cr -3.51TCr -265.75Cr -260.21Cr -11TCr -75Cr -67Cr -62Cr -56Cr -105.31Cr -7.07TCr -106.56Cr -740.58Cr -290.59Cr -3.71TCr -280.85Cr -275.01Cr -12TCr
Projected Income Statement - Annual - Denali Therapeutics Inc.
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
503
Date Price Change Volume
21/26/21 $18.68 -1.32% 14,29,264
20/26/20 $18.93 +4.93% 18,24,103
19/26/19 $18.04 +2.44% 26,88,860
16/26/16 $17.61 -3.98% 23,04,311
15/26/15 $18.34 +2.63% 15,66,182
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Denali Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
18.68USD
Average target price
35.50USD
Spread / Average Target
+90.04%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Denali Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. DNLI Stock